BY COMMUNITY ONCOLOGIST, THE CRBCM IS CLEARLY NOT INCLUDED! THEY KNOW WHO THEY MEAN!

Community Oncologist Education and Support Systems ‐ Renal Cell Carcinoma and Hematologic Malignancies Request for Proposals National Comprehensive Cancer Network and Pfizer Independent Grants for Learning & Change Pfizer and National Comprehensive Cancer Network (NCCN) are collaborating  to offer a new grant opportunity focused on improving care for patients with  rare types of cancer such as renal cell carcinoma (RCC) and certain hematologic  malignancies, where treatment options are complex and rapidly advancing. The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is  to accelerate the adoption of evidence‐based innovations that align the mutual  interests of patients, healthcare professionals, and Pfizer, through support  of independent professional education activities. The term “independent”  means the initiatives funded by Pfizer are the full responsibility of the  recipient organization. Pfizer has no influence over any aspect of the initiatives,  and only asks for reports about the results and impact of the initiatives,  which it may share publicly. NCCN, a not‐for‐profit alliance of twenty‐three (23) of the world’s leading  cancer centers, is dedicated to improving the quality and effectiveness of  care provided to patients with cancer. Through the leadership and expertise  of clinical professionals at NCCN Member Institutions, NCCN develops  resources that present valuable information to the numerous stakeholders  in the health care delivery system. NCCN has access, through its member  institutions, to the world’s leading thought leaders in all areas and aspects  of oncology who are integral to the execution of this program. This Request for Proposals (RFP) is being issued by both organizations. NCCN is  the lead organization for review and evaluation of applications. A review  committee, led by NCCN, will make decisions on which proposals will receive  funding. Grant funding will be provided by Pfizer. Collectively, up to $2 million  is available for the program. Once announced through this distribution list, the RFP will also be  posted on our website at www.pfizer.com/independentgrants  Please  refer to the full text of the RFP for various key dates and submission  instructions. Clinical Areas: Category 1: Oncology Communities – RCC Category 2: Oncology Communities –  Hematologic Malignancies LOI Due Date: December 5, 2013 Please send an email to IGLC@pfizer.com to unsubscribe from this distribution.

RFP Community Oncologist Education and Support Systems.pdf 205K   View   Download